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Acute kidney injury (AKI) is a common clinical 
condition associated with diverse etiologies and 
abrupt loss of renal function. In patients with sepsis, 
rhabdomyolysis, cancer, as well as cardiovascular 
disorders, the underlying disease or associated 
therapeutic interventions can cause hypoxia, 
cytotoxicity, and inflammatory insults to renal 
tubular epithelial cells (RTECs) resulting in the 
onset of AKI. To uncover stress-responsive 
disease-modifying genes, here we have carried out 
renal transcriptome profiling in three distinct 
murine models of AKI. We find that Vgf nerve 
growth factor inducible gene upregulation is a 
common transcriptional stress response in RTECs 
to ischemia, cisplatin, and rhabdomyolysis-
associated renal injury. The Vgf gene encodes a 
secretory peptide precursor protein that has critical 
neuro-endocrine functions; however, its role in the 
kidneys remains unknown. Our functional studies 
show that RTEC-specific Vgf gene ablation 
exacerbates ischemia, cisplatin, and 
rhabdomyolysis-associated AKI in vivo and 
cisplatin-induced RTEC cell death in vitro. 
Importantly, aggravation of cisplatin-induced renal 
injury caused by Vgf gene ablation is partly 
reversed by TLQP-21, a Vgf-derived peptide. 
Finally, in vitro and in vivo mechanistic studies 
showed that injury-induced Vgf upregulation in 
RTECs is driven by the transcriptional regulator 
Sox9. These findings reveal a crucial downstream 
target of the Sox9-directed transcriptional program 
and identify Vgf as a stress-responsive protective 
gene in kidney tubular epithelial cells. 
Introduction 
Acute kidney injury (AKI) is a 
heterogeneous clinical syndrome that is associated 
with adverse short and long-term sequelae (1). AKI 
usually occurs in the setting of other diseases, such 
as sepsis (2), rhabdomyolysis (3), cardiovascular (4) 
and oncological diseases (5), where the underlying 
disease and or associated therapy cause abrupt loss 
of renal function. As a result, the pathophysiology 
of AKI is generally complex due to the existence of 
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multiple etiologies such as the presence of sepsis, 
ischemia, and therapy-induced nephrotoxicity (6). 
AKI-associated mortality depends on the severity 
and can be significantly high in critically ill patients 
(7). Importantly, patients who survive an episode of 
AKI are at increased risk for major adverse 
cardiovascular events, as well as for progression to 
chronic kidney disease (8). 
Disorders such as sepsis, cancer, 
rhabdomyolysis as well as therapeutic interventions 
such as cardiac surgery and chemotherapy are 
associated with inflammatory, toxic, and hypoxic 
insults to renal tubular epithelial cells (RTECs). 
The resulting RTEC dysfunction and cell death are 
the hallmarks of AKI (9). RTEC dysfunction and 
renal impairment clinically manifest as systemic 
electrolyte and fluid imbalances along with 
accumulation of metabolic waste, which can trigger 
multi-organ failure (7). The pathogenesis of AKI is 
multifaceted due to the involvement of various 
intracellular pathways (6,10-12) in RTEC 
dysfunction and cell death (9) as well as the 
contribution of vascular (13-15) and immune cells 
(16,17) in renal impairment.  
Both the etiology and pathophysiology of 
AKI are complex. To identify common stress 
responsive genes, we have carried out genome-
wide transcriptome analysis in three mouse models 
of AKI. Our studies identify the nerve growth 
factor-inducible gene, Vgf (nonacronymic; 
unrelated to VEGF) as a stress-responsive gene that 
is upregulated during ischemic, nephrotoxic, and 
rhabdomyolysis-associated kidney injury. Vgf was 
originally identified as a nerve growth factor (Ngf) 
-inducible gene in a neuroendocrine cell line and is 
expressed in specific neurons and endocrine cells in 
the brain and the periphery (18). Vgf gene encodes 
a precursor polypeptide, which is proteolytically 
cleaved to generate several bioactive peptides, the 
best studied of which are TLQP-21, TLQP-62, and 
AQEE-30 (19). In the central nervous system, the 
secreted Vgf-derived peptides regulate neuronal 
activity, survival and progenitor proliferation (20-
22). Furthermore, germline Vgf knockout mice have 
significantly reduced body weight, increased 
energy expenditure, and are resistant to diet-
induced obesity, indicating that Vgf-derived 
peptides are critical regulators of energy 
homeostasis (20,23). 
Interestingly, the role of Vgf in kidney 
physiology and pathophysiology remains unknown. 
Here, using transcriptome profiling and RTEC-
specific gene ablation studies, we report that Vgf is 
a stress inducible gene that plays a protective role 
during the development of AKI. 
 
Results 
Mouse models of acute kidney injury. To identify 
common stress-induced cellular transcriptome 
changes linked to the pathogenesis of acute kidney 
injury, we sought to perform bulk RNA sequencing 
of renal tissues from distinct murine models of AKI. 
To this end, we utilized the well-characterized 
mouse models of ischemia-reperfusion injury (IRI), 
drug-induced nephrotoxicity (cisplatin), and 
rhabdomyolysis-mediated kidney injury. IRI-
associated AKI results from a generalized or 
localized impairment of oxygen and nutrient 
delivery to the kidneys (6). Cisplatin nephrotoxicity 
results from specific drug uptake (24) and direct 
toxicity to tubular epithelial cells. 
Rhabdomyolysis-associated AKI results from 
skeletal muscle injury and the subsequent 
myoglobin release into the systemic circulation, 
which causes renal dysfunction (3).  
In these mouse models, bilateral ischemic 
surgery, intra-peritoneal cisplatin injection, and 
intramuscular glycerol injection trigger AKI within 
24-72 hours. The development and progression of 
AKI was determined by accumulation of 
nitrogenous waste (blood urea nitrogen and serum 
creatinine) and histological analysis of tissue 
damage (H&E staining and renal damage score). 
During ischemia (Fig. 1A-C) and rhabdomyolysis-
associated (Fig. 1D-F) kidney injury, onset of renal 
impairment occurs 24 hours post-surgery or -
injection, while in the cisplatin-associated kidney 
injury models, renal impairment is observed 72 
hours post-injection (Fig. 1G-I). Histological 
analysis revealed similar tubular damage in IRI (24 
hours), rhabdomyolysis (24 hours) and cisplatin (72 
hours) groups (Fig. 1J). 
Transcriptome profiling of AKI-associated 
differentially expressed genes. Due to temporal 
differences in the onset of kidney injury, we chose 
to compare gene expression signals at time-points 
where the extent of kidney injury is similar in the 












three groups. To this end, we isolated renal tissues 
from control (mock and vehicle, n=8), IRI (24 hours, 
n=4), rhabdomyolysis (24 hours, n=4), and cisplatin 
(72 hours, n=4) treated mice and then performed 
RNA sequencing (4-8 biological replicates). 
Principal component analysis (PCA) showed that 
the biological replicates clustered together across 
groups, signifying a high degree of similarity (Fig. 
2A). Hierarchical clustering (Fig. 2B) revealed both 
divergent and convergent gene signatures between 
control and the three AKI groups. In the three AKI 
conditions (FDR<0.05 and fold change2), we 
identified a common set of 1501 differentially (771 
genes were downregulated and 709 genes were 
upregulated) expressed genes (Fig. 2C). In 
Supplementary Files 1 and 2, we have provided 
the complete list and normalized expression levels 
of all detected and differentially expressed genes. 
Enrichment of genes related to glutathione, 
nicotinamide, and fatty acid metabolism were 
observed upon gene ontology (GO) and KEGG 
pathway analysis (Suppl. File 3). These pathways 
have been recently probed for their role in renal 
dysfunction (25,26). 
To identify previously unexplored genes, 
we initially focused our attention on the top 
differentially expressed genes (DEGs) in the AKI 
conditions. The top common upregulated genes in 
AKI mice were Fosl1, Krt20, Mmp10, 
1700001F09Rik, Sprr2f, Lcn2, Sprr2g, Havcr1, 
Nptx2, and Vgf (Fig. 2D). On the other hand, the top 
common downregulated genes were Ccdc169, 
Pvalb, Egf, Trdn, Inmt, Col6a6, Wfdc16, Pde6a, 
Slc7a13, and Gm6300. The molecular functions of 
some of these DEGs including the widely studied 
injury biomarkers Lcn2 and Havcr1 have been 
explored previously (27,28). We found that similar 
to Havcr1 and Lcn2 upregulation, 200-2000 fold 
induction of Vgf gene expression is observed in the 
three AKI conditions (Fig. 2E-G). Immunoblot 
analysis showed a robust increase in Vgf protein 
levels early during the development of AKI (Suppl. 
Information Fig. 1). These results indicated that 
Vgf is transcriptionally upregulated in response to 
wide-ranging forms of renal injury.  
Stress-induced Vgf upregulation in RTECs during 
AKI. Vgf (nonacronymic) was first identified as a 
nerve growth factor (Ngf) induced gene in a 
neuroendocrine cell line (18). The Vgf gene encodes 
a highly conserved precursor polypeptide of 615 
(human) and 617 (rat and mice) amino acids. The 
precursor polypeptide contains several cleavage 
sites and protease action at these locations results in 
the generation of a number of peptides, which exert 
pleotropic biological activities (19), including 
promotion of pro-survival signaling in an autocrine 
and paracrine fashion (29,30). While Vgf plays 
critical roles in neuronal and endocrine tissues, its 
role in the kidneys remains unknown. 
We initially sought to validate the RNAseq 
data and investigate the cellular origin of Vgf 
mRNA upregulation. To do so, we utilized a 
reporter mouse (31) that express membrane-
localized green fluorescent protein (GFP) in the 
tubular epithelial cells (Fig. 3A). These mice were 
challenged with ischemia, cisplatin, and 
rhabdomyolysis (Suppl. Information Fig. 2) 
followed by isolation of GFP-positive cells from 
the kidneys and subsequent examination of Vgf 
gene expression. We found that Vgf mRNA 
upregulation occurs in RTECs (GFP-positive cells) 
early during the development of AKI (Fig. 3B-D). 
A similar increase in Vgf expression was observed 
when human and murine RTEC cell lines (HK-2 
and BUMPT cells) as well as primary murine 
RTECs were challenged with cisplatin under in 
vitro conditions (Fig. 3E). Based on these results 
we concluded that Vgf upregulation in RTECs is a 
common response to stress in vitro and in vivo. 
Vgf gene deletion in renal tubular epithelial cells 
aggravates AKI. To probe the functional role of 
Vgf in the pathogenesis of AKI, we examined the 
effect of Vgf gene ablation on the severity of AKI. 
To this end, we generated Vgf conditional knockout 
(VgfPT-/-) mice by crossing the Vgf floxed mice with 
the Ggt1-Cre mice. In Ggt1-Cre mice, Cre 
recombinase is expressed in RTECs 7-10 days after 
birth and as a result Cre-mediated gene ablation is 
unlikely to influence normal renal development 
(32). VgfPT-/- mice were indistinguishable from 
wild-type littermates and normal renal function was 
not evidently influenced by Vgf deficiency in 
RTECs (Suppl. Information Fig. 3). Immunoblot 
and immunofluorescence experiments confirmed 
Vgf knockout in RTECs (Fig. 4A-C). However, 
when the control and VgfPT-/- littermates were 
challenged with ischemia, cisplatin- and 
rhabdomyolysis, we observed that Vgf gene 
deletion markedly exacerbates renal injury (Fig. 
4D-I and Suppl. Information Fig. 4). To further 












corroborate these results, we cultured primary 
RTECs from the wild type and VgfPT-/- mice, 
challenged them with cisplatin and then carried out 
viability assays. Cell survival and caspase assays 
(Suppl. Information Fig. 5) showed that Vgf gene 
deletion results in increased cisplatin-induced cell 
death. Thus, we propose that Vgf plays a 
cytoprotective role in RTECs under stress 
conditions associated with AKI.  
Vgf-associated TLQP-21 peptide protects RTECs 
under stress conditions. Vgf has several pleiotropic 
functions in neurons and endocrine cells (18). 
Notably, several Vgf proteolytic peptides have been 
identified and are named by the first 4 N-terminal 
amino acids and their total length (e.g., TLQP-62, 
TLQP-21, HHPD-41, AQEE-11, and LQEQ-19) 
(19). These peptides can influence various cellular 
processes including activation of pro-survival 
signaling under stress conditions (29,30,33,34). 
Some of the biological effects of these Vgf-
associated peptides are believed to be mediated 
through binding to extracellular receptors such as 
the complement-binding protein, gC1qR and 
complement C3a receptor-1 (C3AR1) (35,36).  
We found that TLQP-21 levels were 
increased in the renal tissues of wild type mice 
challenged with ischemia, cisplatin and 
rhabdomyolysis-associated AKI (Fig. 5A). 
Additionally, wild type primary murine RTECs 
secreted TLQP-21 in the medium when challenged 
with cisplatin (Fig. 5B). Interestingly, tissue 
distribution studies in mice have shown that 
intravenously injected TLQP-21 markedly 
accumulates in the kidney (37). This prompted us 
to carry out in vivo ‘add-back’ experiments to 
determine if the TLQP-21 administration can 
reverse the aggravated renal impairment phenotype 
observed in the VgfPT-/- mice. To this end, we 
administered a scrambled peptide (Scr) or TLQP-
21 to control and VgfPT-/- mice, 24 and 48 hours 
after challenging them with cisplatin (Fig. 5C). 
Remarkably, we found that TLQP-21 
administration mitigates cisplatin-associated AKI 
in the VgfPT-/- mice (Fig. 5D-F), indicating that loss 
of TLQP-21 might be partly responsible for the 
increased sensitivity to renal injury. 
Complementary studies in primary murine RTECs 
showed that TLQP-21 treatment can protect Vgf 
deficient RTECs from cisplatin-induced cell death 
(Suppl. Information Fig. 6). These results indicate 
that the loss of TLQP-21 is partly responsible for 
the aggravated renal impairment phenotype seen in 
the Vgf deficient mice. 
VGF regulation by Sox9 in the early acute phase 
of renal injury. Next, we sought to identify the 
transcriptional mechanisms underlying stress-
induced Vgf upregulation in RTECs. While 
exploring the transcription factor binding sites in 
the Vgf promoter, we noticed the presence of a 
putative Sox9 binding site (Fig. 6A).  Sox9 is 
upregulated in RTECs in response to injury and is a 
critical transcriptional regulator of epithelial cell 
fate during AKI (31,38-41). To test the hypothesis 
that Sox9 is involved in Vgf upregulation during 
AKI, we performed promoter-driven luciferase-
based reporter assays (Fig. 6B) in HEK293 cells, 
which have low endogenous Sox9 expression. To 
this end, we used HEK293 cells with stable vector 
transfection (low Sox9) and Sox9 overexpression 
(high Sox9) for Vgf promoter driven luciferase 
reporter assays as described in our recent study (31). 
We found that Sox9 increases Vgf promoter activity 
(Fig. 6C). Importantly, site-directed mutagenesis of 
Sox9 binding site within the Vgf promoter 
suppressed promoter activity. To substantiate these 
findings, we performed chromatin 
immunoprecipitation analysis, which confirmed 
Sox9 binding at the Vgf promoter in vivo (Fig. 6D).  
We next asked if RTEC-specific Sox9 
deficiency influences stress responsive Vgf 
upregulation. Our recent study (31) revealed a 
protective role of Sox9 during ischemic and 
nephrotoxic AKI. We also found that RTEC-
specific Sox9 gene deletion aggravates 
rhabdomyolysis-associated AKI (Suppl. 
Information Fig. 7). When we carried out gene 
expression analysis of renal tissues from control 
and Sox9PT-/- mice, we found that stress-induced 
Vgf upregulation is Sox9 dependent (Fig. 6E-G). 
Sox9-deficient mice had greater than 95% 
reduction in Vgf mRNA levels.  Furthermore, 
immunoblot analysis in control and Sox9-deficient 
renal tissues showed that injury-induced Vgf 
upregulation is Sox9 dependent (Fig. 6H). Taken 
together, these data indicate that Sox9 controls Vgf 
gene transcription in RTECs during AKI.  
The Sox9-Vgf axis is conserved in human RTECs.  
We next investigated the Sox9-Vgf axis in 
a human RTEC cell line (HK-2). In these cells 












cisplatin treatment resulted in Vgf protein induction, 
which we were able to suppress by transfecting the 
cells with two Vgf specific siRNAs (Fig. 7A). We 
then examined the effect of Vgf knockdown on 
cellular sensitivity to cisplatin. Cell survival and 
caspase assays showed that Vgf knockdown results 
in increased cell death in response to cisplatin 
treatment (Fig. 7B-D). We subsequently explored 
the role of Sox9 in cisplatin-induced Vgf 
upregulation. To this end, we transfected HK-2 
cells with control or Sox9 targeting siRNAs, 
followed by cisplatin treatment. Immunoblot 
analysis confirmed RNAi-mediated Sox9 
knockdown (Fig. 7E). It also showed that cisplatin-
mediated Vgf upregulation was Sox9-dependent 
(Fig. 7E). Importantly gene expression analysis 
confirmed that Sox9 knockdown suppresses Vgf 
mRNA upregulation (Fig. 7F). Furthermore, 
bioinformatics analysis identified a putative Sox9 
target site in the human Vgf promoter (Fig. 7G). 
Promoter-based luciferase assay showed that Sox9 
increases Vgf promoter activity, which was 
inhibited when the Sox9 binding site was mutated 
(Fig. 7H). Finally, Vgf upregulation in response to 
injury was confirmed in a porcine model of 
ischemia AKI (42) and a human organoid (43,44) 
model of cisplatin-associated injury (Suppl. 
Information Fig. 8). Collectively, these studies 
with multiple mouse models of AKI, primary 
murine RTECs, human RTEC cell line (HK-2), 
porcine AKI model, and human organoids suggests 
that stress-mediated Vgf upregulation is likely a 
conserved and protective mechanism in RTECs.  
Discussion 
Here we have mapped the transcriptome 
changes accompanying the development of 
ischemic, nephrotoxic, and rhabdomyolysis 
associated acute kidney injury. We find that these 
diverse stress conditions trigger transcriptional 
upregulation of Vgf gene in renal tubular epithelial 
cells.  Importantly, we provide functional evidence 
that Sox9-mediated Vgf upregulation protects 
RTECs from cell death and dysfunction linked with 
AKI. These findings identify Vgf as an essential 
stress-responsive and protective gene in kidney 
epithelial cells. 
Spatial and temporal changes in gene 
expression in response to ischemia reperfusion 
associated kidney injury has been comprehensively 
explored (39,45). Since multiple etiologies can 
contribute to the development of AKI, in the current 
study, we aimed to identify common transcriptional 
changes that occur in the acute phase of three 
distinct murine models of AKI. Consistent with 
previous studies (39,45), we observed that genes 
such as Sprr2f and Krt20 and well-characterized 
renal injury biomarkers such as Lcn2 and Havcr1 
were significantly upregulated during ischemic, 
nephrotoxic, and rhabdomyolysis associated acute 
kidney injury. Furthermore, pathway enrichment 
analysis revealed that genes linked to cell death and 
survival, wound healing, small molecule and fatty 
acid metabolism, and molecular transport were 
differentially expressed during AKI.  
Vgf was among the top upregulated genes 
in the renal tissues of mice undergoing ischemic, 
nephrotoxic, and rhabdomyolysis-associated AKI. 
The Vgf gene is known to be expressed in a subset 
of cells in the central and peripheral nervous system 
as well as endocrine cells in the adrenal gland, 
gastrointestinal tract, and pancreas (18). Within the 
nervous system, Vgf expression is rapidly induced 
by neurotrophins, synaptic activity, nerve injury, 
inflammation, and other stimuli (21). Consistent 
with its expression in the central and peripheral 
nervous system, Vgf has been implicated in the 
regulation of neuroplasticity associated with 
learning, memory, depression, and chronic pain 
(21,46,47). Additionally, Vgf plays a critical role in 
energy homeostasis and metabolism (23,34,48). 
Mice with germline Vgf deletion are lean, hyper-
metabolic, and resistant to diet-, lesion-, and 
genetically induced obesity and diabetes (20). 
Interestingly, the role of Vgf in renal physiology 
and pathology has remained unexplored. 
We found that Vgf expression is low in the 
normal adult kidneys. Moreover, renal epithelial-
cell-specific Vgf deficiency did not have any 
deleterious effect on the normal kidney structure or 
function and did not alter the overall body weight. 
Importantly, Vgf expression increased by more than 
500 fold in RTECs during ischemic, nephrotoxic, 
and rhabdomyolysis associated AKI. A previous 
study (39) also described Vgf gene induction during 
IRI, however, its functional role in the pathogenesis 
remained unknown. We find that RTEC-specific 
Vgf deletion markedly aggravated renal impairment 
linked with ischemic, nephrotoxic, and 
rhabdomyolysis-associated AKI. Notably, stress-












responsive Vgf upregulation was recapitulated in 
human and murine cell culture models of cisplatin 
associated cellular injury. Functional studies also 
showed that Vgf deficiency sensitizes RTECs to 
cisplatin-mediated cell death. These studies reveal 
that Vgf protects RTECs from cell death and 
dysfunction. 
The neuro-endocrine functions attributed 
to the Vgf gene are dependent on the post-
translational processing of Vgf polypeptide into 
various bioactive peptides, such as TLQP-21, 
TLQP-62, AQEE-30, LQEQ-19, and NERP2. 
Among these, TLQP-21 is known to control 
regulatory processes involved in energy 
expenditure, lipolysis, glucose-stimulated insulin 
secretion, gastric acid secretion and pain (34,47,49). 
We found that along with Vgf mRNA, TLQP-21 
levels also increase in the renal tissues during AKI. 
Strikingly, systemic TLQP-21 administration partly 
reversed the injury-induced aggravation of renal 
impairment observed in the RTEC-specific Vgf-
deficient mice. These findings suggest that Vgf-
derived TLQP-21 plays a protective role during 
AKI. A critical feature of Vgf peptides is their cell 
type specific diversity in tissues studied so far and 
their selective modulation in response to organ or 
cell type relevant stimuli (19). Future studies are 
thus necessary to comprehensively profile Vgf 
derived peptides in renal tissues under normal and 
stress conditions. 
The underlying signaling mechanisms 
associated with the myriad neuro-endocrine 
functions of Vgf remains incompletely understood. 
At least some of the biological functions of Vgf 
derived peptides are mediated through extracellular 
receptor binding. Indeed,   complement C3a 
receptor 1 (C3aR1) has been identified as a TLQP-
21 receptor on microglia and other cell types 
(35,50-52). For example, in the adipose tissue, 
TLQP-21 exerts an anti-obesity effect in diet-
induced obese mice through binding to C3aR1 and 
inducing β-adrenergic receptor expression (53). 
Furthermore, C1qR, the globular heads of the C1q 
receptor has been identified as a TLQP-21 receptor 
in macrophages (36). Interestingly, a previous study 
has shown that C3aR1 is expressed in RTECs and 
germline C3aR1 gene ablation provides protection 
from ischemia-associated AKI (54).  It is well 
established that complement activation within the 
injured kidneys trigger downstream inflammatory 
events within the renal parenchyma that exacerbate 
renal cell dysfunction and cell death (55,56). Future 
studies with cell type specific conditional knockout 
mice are required to tease out the possible role of 
C3aR1, C1qR, or other proteins as receptors of Vgf-
derived peptides in the kidney.  
How Vgf protects renal epithelial cells 
under stress conditions in vivo remains unclear. Our 
studies with cultured primary epithelial cells 
suggest that stress conditions trigger the induction 
of Vgf-derived TLQP-21, which might function in 
an autocrine and or paracrine manner to protect 
RTECs from cisplatin-associated cell death. 
However, these epithelial cell culture models of 
injury do not completely recapitulate the in vivo 
pathophysiological complexities of AKI, 
particularly the involvement of other cell types such 
as immune cells (57-59). Therefore, our studies do 
not rule out the possibility that Vgf and TLQP-21 
might influence renal injury through crosstalk 
between epithelial and immune cells. Interestingly, 
in peripheral neurons, inflammatory conditions can 
cause Vgf upregulation and Vgf can in turn 
functionally regulate inflammatory processes (60). 
Altogether, our study provides strong evidence for 
the protective role of RTEC-derived Vgf in AKI, 
however, the further unravelling of this pathway 
will require the identification of underlying 
receptors, modulated cell types and intracellular 
signaling pathways.     
While the downstream pathways remain 
unclear, we propose that Sox9 is the critical 
transcriptional regulator of stress-induced Vgf 
upregulation in RTECs. Several lines of evidence 
suggest that Sox9 directly binds to the Vgf promoter 
and promotes the transcriptional up-regulation of 
Vgf gene. Firstly, injury-induced Vgf upregulation 
was significantly suppressed in renal tissues of 
RTEC-specific conditional Sox9 knockout mice. 
Secondly, chromatin immunoprecipitation studies 
showed Sox9 enrichment at the Vgf promoter site in 
vivo. Thirdly, luciferase reporter assays confirmed 
Sox9 mediated transactivation of Vgf promoter, 
which was suppressed by mutations in the Sox9 
binding site. These results establish Vgf as a bona 
fide Sox9 target gene in RTECs.  
In the current study, we find that Vgf 
deficiency exacerbates AKI, a phenotype that is 
similar to the RTEC-specific Sox9 deficient mice 












(31). However, Sox9 is a crucial transcriptional 
regulator of not only the early pathogenic phase 
(31), but also the later recovery phase of AKI 
(38,40). Sox9 expressing RTECs are involved in 
the repair and regeneration processes post-AKI 
(38,40). Based on our findings that Vgf is a 
downstream Sox9 target gene, it will be interesting 
to examine if Vgf contributes to repair and 
regeneration. It would also be interesting to 
examine if the systemic TLQP-21 administration 
can accelerate the recovery and repair processes 
post-AKI. Collectively, our study has revealed Vgf 
as an essential Sox9 target gene that protects 
RTECs under stress conditions associated with 
acute kidney injury. 
 
Experimental procedures 
Cell culture and reagents. Boston University 
mouse proximal tubule cells (BUMPT, clone 306, 
generated by Drs. Wilfred Lieberthal and John 
Schwartz, Boston University School of Medicine, 
Boston, MA, were obtained from Dr. Zheng Dong, 
Augusta University, Augusta, GA) were grown at 
37 °C in Dulbecco’s modified Eagle’s medium with 
10% fetal bovine serum. The human renal tubular 
cell line, HK-2 cells (ATCC, CRL-2190) were 
grown in keratinocyte media (K-SFM) according to 
the provider’s instructions. HEK293 cells stably 
transfected with empty vector (pCMV6) or Sox9 
expression vector have been described in our 
previous study (31) and were grown at 37 °C in 
Dulbecco’s modified Eagle’s medium with 10% 
fetal bovine serum. Cisplatin, glycerol, TLQP-21 
(murine), and other reagents were obtained from 
Sigma-Aldrich. 
Primary murine tubular cell culture. Murine renal 
cortical tissues were minced and digested with 
0.75 mg/ml collagenase IV (Thermo-Fisher 
Scientific). Cells were centrifuged at 2000 g for 
10 min in DMEM/F-12 medium with 32% Percoll 
(Amersham). After two washes with serum-free 
media, the cells were plated in collagen-coated 
dishes and cultured in DMEM/F-12 medium 
supplemented with 5 μg/ml transferrin, 5 μg/ml 
insulin, 0.05 μM hydrocortisone, and 50 μM 
vitamin C (Sigma-Aldrich). Fresh media was 
supplemented every alternate day, and after 5–7 
days of growth, the isolated proximal tubular cells 
were trypsinized and re-plated at 1 × 105 cells per 
well in 24-well plates. To induce cell death, primary 
RTECs were incubated with 50 μM cisplatin 
(Sigma-Aldrich) in fresh culture medium for 24 h, 
followed by viability and caspase assays. 
siRNA Transfection, Cell viability and caspase 
assays. Transient transfections and cell viability 
assays were performed according to methods 
described in our previous study (31). Briefly, the 
HK-2 cells were plated in 24 or 96-well plates and 
reverse-transfected with 25 nM siRNA (Sigma) 
using Lipofectamine RNAiMAX reagent (Life 
Technologies). At 48 h post transfection, cells were 
treated with 50 µM cisplatin in fresh media. 
Subsequently, 48 h post treatment, cell viability 
assays and immunoblot analysis were performed. 
At the end of the incubation period, cells from 24-
well plates were harvested, followed by trypan blue 
staining and manual cell counting with a 
hemocytometer and/or by using Countess 
Automated Cell Counter (Thermo Fisher); 
translucent cells were considered as viable and 
blue-stained cells were counted as dead. Cellular 
viability was calculated by dividing the number of 
viable cells by the total cell number and each 
sample was done in triplicate. For MTT assays, 
after cisplatin treatment in 96-well plates, 10 μL of 
MTT reagent (5 mg/mL MTT in PBS) was added to 
each well, and plates were incubated at 37 °C with 
5% CO2 for 4 h, followed by addition of 100 μl of 
acidified isopropanol (Sigma-Aldrich) and 
measurement of absorbance at 590 nm. The half-
maximal inhibitory concentration (IC50) was 
calculated by nonlinear regression analysis using 
GraphPad Prism.  
For caspase assays (61), cells were lysed in a buffer 
containing 1% Triton X-100, and 10 μg of protein 
from cell lysates was added to an enzymatic assay 
buffer containing 50 μM DEVD-AFC for 60 min at 
37 °C. Fluorescence at excitation 360 nm/emission 
535 nm was measured, and free AFC was used to 
plot a standard curve. Subsequently, the standard 
curve was used to convert the fluorescence reading 
from the enzymatic reaction into the nM AFC 
liberated per mg protein per hour as a measure of 
caspase activity. 
Mice strains and breeding. Mice were housed in a 
temperature-controlled environment with a 12 hour 












light cycle and were given a standard diet and water 
ad libitum. All animal experiments were carried out 
in accordance with the animal use protocol 
approved by the Institutional Animal Care and Use 
Committee of the Ohio State University. C57BL/6J 
mice, Vgf floxed mice, Sox9 floxed mice and Ggt1-
Cre transgenic mice (stock numbers 000664, 
030571, 013106 and 012841, respectively) were 
obtained from Jackson Laboratories. Vgf floxed 
mice and Sox9 floxed mice were bred with Ggt1-
Cre transgenic mice to generate conditional gene 
knockout mice in renal tubular epithelial cells. 
These transgenic mice express Cre recombinase in 
the renal tubular epithelial cells beginning at age 1-
2 weeks. mT/mG mice that express membrane-
targeted, two-color fluorescent Cre-reporter allele 
were obtained from Jackson Laboratories (stock no. 
007676). The mT/mG mice were bred with Ggt1-
Cre strain as reported previously (31). For all 
mouse colonies, the pups were ear tagged and 
genotyped at 3 weeks of age. Offspring were 
genotyped by standard PCR-based methods. 
Primers used for amplification were Vgf36100 (5′-
TCC TCC CTC TCA GTG TTT GC-3′) and 
Vgf36101 (5′-GGA CTC GCA CAA ACC ACA C-
3’) and yield a 313-bp product for the Vgf floxed 
allele, and a 194-bp product for the Vgf wild-type 
allele. Sox9-11576 (5’- AGA CTC TGG GCA AGC 
TCT GG-3’) and Sox9-11577 (5’-GTC ATA TTC 
ACG CCC CCA TT-3’) were used for 
amplification and yield a 300-bp product for Sox9 
floxed allele and a 250-bp product for the Sox9 
wild-type allele. Primers for Ggt1-Cre are Cre5’ 
(AGG TGT AGA GAA GGC ACT TAG C), Cre3’ 
(CTA ATC GCC ATC TTC CAG CAG G) and 
produce a 405-bp product. PCR products were 
analyzed by electrophoresis using 1.5% agarose 
gels. 
Animal models of acute kidney injury. We carried 
out all the studies presented here in age-matched 
male mice at 8-12 weeks of age using methods 
described in our recent studies (31,62,63). In all the 
studies with conditional Vgf and Sox9 knockout 
mice, we used male littermates from mice bred in-
house. Experiments were carried out in a blinded 
fashion where the investigators assessing, 
measuring or quantifying experimental outcomes 
were blinded to the genotype or treatment of the 
mice. For ischemia-reperfusion experiments, mice 
were anesthetized by isoflurane and placed on a 
surgical platform where the body temperature was 
monitored throughout the procedure. The skin was 
disinfected, kidneys were exposed and bilateral 
renal pedicles were clamped for 30 minutes. 
Consequently, the clamps were removed to initiate 
reperfusion followed by suturing to close the 
muscle and skin around the incision. To 
compensate for the fluid loss, 0.5 ml warm sterile 
saline was administered via intraperitoneal 
injection. Blood was collected on day 1 via cardiac 
puncture after carbon dioxide asphyxiation. Renal 
tissues were collected and processed for RNA-seq, 
qPCR, and histological analysis as described 
previously. For nephrotoxicity experiments, 
cisplatin (30 mg/kg) was administered by i.p. 
injection as described previously. After cisplatin 
injection, blood was collected on days 0-3 by 
submandibular vein bleed or on day 3 via cardiac 
puncture after carbon dioxide asphyxiation. Renal 
tissues were collected and processed for RNA-seq, 
qPCR, and histological analysis. To induce 
rhabdomyolysis, 8-12 weeks old male mice were 
injected with 7.5 ml/kg 50% glycerol 
intramuscularly to the two hind-legs or injected 
with saline as a control, followed by tissue 
collection at 24 hours and RNA-seq, qPCR, and 
histological analysis. The porcine model of 
ischemic AKI has been described previously (42). 
We utilized the renal cortical tissues from porcine 
kidneys for qPCR based analysis of Sox9 and Vgf 
genes. 
Assessment of renal damage. Renal damage was 
assessed by serum analysis (blood urea nitrogen 
and creatinine) and histological examination (H&E 
staining). Mouse blood samples were collected at 
indicated time-points, followed by blood urea 
nitrogen and creatinine measurement by 
QuantiChromTM Urea Assay Kit (DIUR-100) and 
Creatinine Colorimetric Assay Kit (Cayman 
Chemical). For histological analysis, mouse 
kidneys were harvested and embedded in paraffin 
at indicated time-points before and after AKI 
induction. Tissue sections (5 μm) were stained with 
hematoxylin and eosin by standard methods (63). 
Histopathologic scoring was conducted by in a 
blinded fashion by examining ten consecutive 100x 
fields per section from at least three mice per group. 
Tubular damage was scored by calculation of the 
percentage of tubules that showed dilation, 
epithelium flattening, cast formation, loss of brush 












border and nuclei, and denudation of the basement 
membrane. The degree of tissue damage was scored 
based on the percentage of damaged tubules as 
previously described: 0: no damage; 1: <25%; 2: 
25–50%; 3: 50–75%; 4: >75%. 
RNA-seq. Total RNA was isolated from harvested 
renal cortical tissues using the RNeasy Plus Mini 
Kit (Qiagen, Germantown, MD, USA) according to 
the manufacturer’s protocols. Total RNA samples 
used for library construction and sequencing (Quick 
Biology, Pasadena, CA). RNA integrity, quality 
and purity were analyzed by Agilent 2100 
Bioanalyzer. Libraries for RNA-Seq were prepared 
with KAPA Stranded mRNA-Seq Kit (KAPA 
Biosystems, Wilmington, MA) according to the 
manufacturer’s protocols. The workflow consisted 
of mRNA enrichment using bead capture for poly-
A selection, cDNA generation, end repair to 
generate blunt ends, A-tailing, adaptor ligation and 
PCR amplification of library fragments. Final 
Library size distribution was determined by using 
an Agilent 2100 Bioanalyzer using the High-
Sensitivity DNA Kit and its quantity was analyzed 
by Life Technologies Qubit 3.0 Fluorometer. 
Libraries were pooled and sequenced on the 
Illumina HiSeq 4000 platform to obtain 150-bp 
paired-end reads, 20 million reads (10 million reads 
pairs) per sample.  
Bioinformatics analysis. Sequencing data quality 
checks were performed by using FastQC followed 
by read alignments using Bowtie2 version 2.1.0 
with alignment to the mouse Ensembl genome 
(GRCm38/mm10). The overall mapping rate of 
more than 80% and rRNA percentage less than 5% 
was considered as good quality mapping data. The 
reads were first mapped to the latest UCSC 
transcript set using Bowtie2 (version 2.1.0) and the 
gene expression level was estimated using RSEM 
v1.2.15. Differentially expressed genes were called 
for each time point with Bioconductor edgeR. 
TMM (trimmed mean of M-values) method in 
edgeR package was used to normalize the gene 
expression results. For all the analyses, we only 
kept genes with (a) FDR-transformed P values 
below 0.05, (b) fold change of at least 1.5, and (c) 
TMM above 1 in three distinct AKI and/or control 
samples. These values of fold change and TMM 
thresholds were chosen to enable experimental 
validation of our differential-expression calls. We 
used the fold changes calculated by edgeR to create 
a pre-ranked gene-list.  Each list of differentially 
expressed genes derived from the different 
comparisons were subjected to functional and 
biochemical pathway analysis using the Gene 
Ontology (GO) and KEGG, Reactome pathway 
databases. Goseq was used to perform the GO 
enrichment analysis and Kobas was used to perform 
the pathway analysis. The RNA-Seq data have been 
deposited in the Gene Expression Omnibus 
(GSE153625). 
qPCR analysis. One microgram of total RNA from 
renal cortical tissues or cultured RTECs was 
reversed transcribed using RevertAid First Strand 
cDNA Synthesis Kit (Thermo-Fisher Scientific) 
and qRT-PCR was run in QuantStudio 7 Flex Real-
Time PCR System (Thermo-Fisher Scientific) 
using SYBR Green Master Mix and gene-specific 
primers. The expression levels of the samples were 
determined by the comparative CT (CT) method. 
-actin was used as the internal control. For gene 
expression analysis in RTECs in vivo, anti-GFP 
antibody and MACS columns (Miltenyi Biotech) 
were used to isolate GFP-positive tubular epithelial 
cells from the kidneys of reporter mice with 
membrane localized EGFP as reported previously 
(31). 
Immunoblot analysis and ELISA. Whole-cell 
lysates from renal cortical tissues were prepared 
using modified RIPA buffer (20 mM Tris-HCl (pH 
7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM 
EGTA, 1% NP-40, 2.5 mM sodium pyrophosphate, 
1 mM beta-glycerophosphate, protease, and 
phosphatase inhibitors) supplemented with 1% 
SDS. Invitrogen Bis-Tris gradient midi-gels were 
used for western blot analysis, followed by the 
detection by ECL reagent (Cell Signaling). Primary 
antibodies used for western blot analysis were from 
Santa Cruz Biotech: Vgf (sc-365397), and β-actin 
(47778) and were used at 1:1,000 dilution. 
Secondary antibodies were from Jackson Immuno-
research and were used at 1:2,000 dilutions. 
Densitometric analysis was carried out using Image 
J, and the signals of target protein were normalized 
to actin levels in the same samples.  
For measurement of TLQP-21 secretion in the 
media, primary murine RTECs were treated with 
vehicle or 50 µM cisplatin followed by media 
collection after 12 hours. Secreted TLQP-21 was 












assayed from the media using a mice TLQP-21-
specific ELISA (Peninsula Laboratories 
International, S-1477) and normalized to cellular 
protein levels (BCA assay, Thermo Fischer). 
Similar methodology was used to measure TLQP-
21 levels in cellular lysates. Vgf knockout samples 
were used as negative controls in all the 
experiments and TLQP-21 levels were undetected 
in the Vgf deficient cells and tissues. 
Immunofluorescence staining. Vgf 
immunostaining was performed according to 
methods described previously (64). Briefly, frozen 
renal tissues were cryosectioned and fixed with 4% 
paraformaldehyde, followed by permeabilization 
with 1% Triton X-100. Subsequently, the tissue 
sections were sequentially incubated with a 
blocking buffer, the Vgf antibody (Santa Cruz 
Biotech, sc-365397), and FITC-labeled anti-mouse 
secondary antibody (Abcam, ab6785), and 
mounting with DAPI containing fluoroshield media 
(Abcam, ab104139). The staining was then 
examined by fluorescence microscopy. Vgf 
knockout tissues were used as negative controls and 
did not have any positive Vgf staining. 
TLQP-21 addback experiments. Murine purified 
TLQP-21 (Sigma, T1581) and a scrambled control 
peptide (GenScript) were used for addback 
experiments. For in vivo experiments, littermate 
control and Vgf deficient male mice (8-12 weeks) 
were injected with cisplatin (30 mg/kg, 
intraperitoneal). Twelve hours later, TLQP-21 or 
control scrambled peptide was administered by 
intraperitoneal injection (4.5 mg/kg). Renal tissues 
and blood were collected at 72 hours post cisplatin 
injection, followed by assessment of renal damage. 
For in vitro experiments, primary RTECs were 
sequentially treated with 50 µM cisplatin (or 
vehicle), followed by TLQP21 or Scrambled 
peptide (25 nM) treatment four hours later and 
assessment of cellular viability at 24 or 48 hours. 
 Promoter Luciferase Assay. HEK293 cells were 
stably transfected with either empty vector 
(pCMV6) or Sox9 expression vector (Origene). 
These cells were then utilized for promoter 
luciferase reporter assays using methods reported in 
our recent studies (31,65). Briefly, (5 × 103) were 
plated overnight on white poly-l-lysine-coated 96-
well plates, followed by transient transfection with 
either promoter constructs (Switchgear Genomics, 
encoding approximately 2 kb sequence upstream of 
transcription start site of Vgf) or empty promoter 
construct at 30 ng in combination with the 
Cypridina TK control construct (Switchgear 
Genomics) at 1 ng, according to the manufacturer’s 
protocol (Switchgear Genomics, Lightswitch Dual 
Assay kit, DA010). The promoter construct 
encodes a Renilla luminescent reporter gene, called 
RenSP, while the transfection and normalization 
vector encodes a Cypridina luciferase. The Renilla 
luciferase activity was normalized to the Cypridina 
luciferase activity.  
Site directed mutagenesis. The QuikChange II XL 
Site-Directed Mutagenesis Kit (Agilent) was 
utilized to generate Vgf promoter mutants, 
according to previously described methods (66). 
The QuikChange primer design program was used 
to design mutagenesis primers and primers were 
synthesized by Integrated DNA Technologies. 
Mutant constructs were sequenced to confirm 
successful mutagenesis. The primers used for Sox9 
binding site mutagenesis (ATTGTT to AAACAT) 





ATGGACCAGGGAACA-3’ and human promoter 





Chromatin immunoprecipitation (ChIP). ChIP 
assays were performed using the Pierce Magnetic 
ChIP Kit according to the manufacturer’s 
instructions and our previous studies (31,65). 
Briefly, cross-linking with 1% formaldehyde was 
carried out in renal tissues, followed by quenching 
with glycine, harvesting, and DNA fragmentation 
by sonication. Tissue lysates were precleared for 
2 h with Protein A + G magnetic beads (EMD 
Millipore). Precleared lysates were then incubated 
with 5 μg of anti-Sox9 antibody (Abcam, ab3697) 
overnight at 4 °C, followed by addition of Protein 
A + G magnetic beads and incubation for 4 h at 4 °C. 
Finally, the beads were collected, repeatedly 
washed and the protein–DNA complexes were 
eluted, cross-links were reversed and the DNA was 
purified. Standard qPCR analysis was then carried 












out using the following primers spanning the Vgf 
promoter: 5’-TCCCAGGCTGATGTGAACTT-3’ 
and 5’-TCACCAGGCATGCCCATAAG-3’. 
Human kidney organoid cultures and epithelial 
cell isolation. All work was carried out with the 
approval of the University of Auckland Human 
Participants Ethics and Health and Disability Ethics 
Committees (UAHPEC 8712 and HDEC 
17/NTA/204, respectively) and the University of 
Auckland Biological Safety Committee. Kidney 
organoids were generated from the MANZ-2 iPSC 
line and day 12 organoids were treated with 4x 5 
µM cisplatin over 7 days to induce AKI as 
described previously (43,67). On day 19, epithelial 
cells were isolated using EPCAM Magnetic-
Activated Cell Sorting (MACS) as described 
previously (68). Briefly, organoids were 
enzymatically dissociated and  the cell suspension 
was then passed sequentially through 100, 40, 20 
µm cell strainers and centrifuged for 10 min at 300 
x g. Cells were resuspended in 250 µL MACS 
buffer plus 50 µL of EPCAM (CD326) microbeads 
(Miltenyi Biotech) and incubated for 30 min at 4oC. 
Cells were washed with MACS buffer and 
centrifuged twice prior to resuspension in 500 µL 
MACS buffer. The cell suspension was then passed 
through an MS MACS column according to the 
manufacturer’s instruction (Miltenyi Biotec). The 
flow-through (EPCAM -ve fraction) was collected, 
and the EPCAM +ve fraction was eluted with 1 mL 
MACS buffer from the column. The EPCAM -ve 
and EPCAM +ve fractions were pelleted by 
centrifugation at 300 x g for 10 min. Total RNA was 
prepared from EPCAM +ve cells and quantitative 
PCR was performed with gene-specific primers. 
Gene expression was determined by the 
comparative CT (CT) method using HPRT1 as 




SOX9 (5’-AGCGAACGCACATCAAGAC-3’ and 
5’-CTGTAGGCGATCTGTTGGGG-3’), and VGF 
(5’-CCTTCCCGAAACCCACAAGTT-3’ and 5’-
GCCTTGGTACGCCTTGGAC-3’). 
Statistical Analysis. Data in all the graphs are 
presented as mean with s.e.m, unless stated 
otherwise. Statistical calculations were carried our 
using GraphPad Prism. p<0.05 was considered as 
statistically significant. To calculate statistical 
significance between two groups, two-tailed 
unpaired Student’s t test was performed. One-way 
ANOVA followed by Tukey’s or Dunnett’s 
multiple-comparison test was used for comparisons 
among three or more groups. No sample outliers 
were excluded. 
Data Availability 
The RNA-Seq data have been deposited in the Gene 
Expression Omnibus (GSE153625). In addition, the 
rest of data are contained within the manuscript. 
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Figure 1: Mouse models of acute kidney injury. Ischemic, nephrotoxic, and rhabdomyolysis-associated 
acute kidney injury was induced in 8-12 weeks old male C57BL/6J mice. Bilateral renal ischemia (30 
minutes) was induced for 30 min followed by reperfusion for 24 hours. Blood urea nitrogen (A), serum 
creatinine (B), and histological analysis (C) were performed to examine renal function and damage. 
Rhabdomyolysis was induced in male mice by glycerol injection (7.5 ml/kg 50% glycerol) in the hind-leg 
muscles followed by measurement of renal function (D-E) and histological analysis (F) of renal damage. 
Nephrotoxicity was induced in mice by a single intraperitoneal injection of cisplatin (30 mg/kg), followed 
by BUN (G), serum creatinine (H), and histological analysis (I) at the indicated time-points.  (J) 
Representative H&E staining depicting renal tubular damage (indicated by an asterisk) linked with ischemia, 
cisplatin-nephrotoxicity, and rhabdomyolysis associated AKI. In all the bar graphs (n=8 biologically 
independent samples), experimental values are presented as mean ± s.d. The height of error bar = 1 s.d. and 
p < 0.05 was indicated as statistically significant. Student’s t-test (A-I) was carried out and statistical 
significance is indicated by *p < 0.05, **p < 0.01, ***p < 0.001. Scale bar (J): 100 µm.  
Figure 2: Transcriptome analysis of AKI-associated differentially expressed genes. Renal cortical 
tissues from control (mock and vehicle treated) mice and mice undergoing AKI (IRI, cisplatin 
nephrotoxicity, and rhabdomyolysis) were utilized for transcriptome analysis. (A) Principal component 
analysis (PCA) of bulk RNA-Seq data from control (n=8) and AKI (n=4) groups showed that biological 
replicates clustered together across groups, signifying a high degree of similarity. (B) Heatmap of 
differentially expressed genes during AKI. (D) Graphical depiction of top up-and down-regulated genes in 
three distinct AKI models. (C) Venn diagram depicting common differentially expressed genes in the AKI 
groups. In the three AKI groups, a common set of 1501 genes were found to differentially expressed as 
compared to control group. (E-G) Gene expression analysis of Havcr1, Lcn2, and Vgf genes showed injury 
induced upregulation. In all (E-G) the bar graphs (n=4 biologically independent samples), experimental 
values are presented as mean ± s.d. The height of error bar = 1 s.d. and p < 0.05 was indicated as statistically 
significant. One-way ANOVA followed by Dunnett’s (E-G) was carried out, and statistical significance is 
indicated by *p < 0.05, **p < 0.01, ***p < 0.001.  













Figure 3: Vgf is upregulated in the tubular epithelial cells during AKI.  ROSAmT/mG were crossed with 
Ggt1-Cre mice to generate transgenic mice that express membrane-localized EGFP in renal tubular 
epithelial cells, while the other cell types express membrane localized tdTomato. (A) Representative image 
showing EGFP expressing renal tubules (arrows) and tdTomato expression in the glomerulus (asterisks). 
(B-D) Renal Vgf expression was monitored at indicated time-points using qPCR-based analysis.  The results 
demonstrate Vgf gene induction during the early stages of AKI. (E) Human (HK-2) and murine (BUMPT) 
tubular epithelial cell lines as well as murine primary tubular epithelial cells were treated with either vehicle 
(PBS) or 50 µM cisplatin followed by gene expression analysis at 12 hours. Cisplatin treatment in vitro 
resulted in Vgf mRNA induction in both the cell lines as well as primary tubular epithelial cells. In all the 
bar graphs (n=10-11 biologically independent samples), experimental values are presented as mean ± s.d. 
The height of error bar = 1 s.d. and p < 0.05 was indicated as statistically significant. One-way ANOVA 
followed by Dunnett’s (B-D) or Student’s t-test (E) was carried out, and statistical significance is indicated 
by *p < 0.05, **p < 0.01, ***p < 0.001. Scale bar (A): 100 µm.  
Figure 4: RTEC-specific Vgf gene ablation aggravates AKI. RTEC-specific Vgf knockout mice were 
generated by crossing Ggt1-Cre mice with Vgf-floxed mice. 8-12 weeks old littermate control and Vgf 
conditional knockout male mice (indicated by VgfPT−/-) were then challenged with bilateral renal ischemia 
(30 minutes), cisplatin (30 mg/kg, single intraperitoneal injection) treatment, or glycerol-induce 
rhabdomyolysis (7.5 ml/kg 50% glycerol in the hind-leg muscles) followed by examination of renal 
structure and function. (A-B) Immunoblot analysis of Vgf protein levels was performed using renal cortical 
tissues from the control and Vgf deficient mice followed by densitometric analysis (normalized to β-actin 
levels) using ImageJ. The graph depicts relative Vgf protein levels and shows successful gene knockout in 
the renal tissues. Blots are representative of three independent experiments. (C) Immunofluorescence 
analysis of renal cortical tissues from control and VgfPT-/- mice challenged with IRI shows that Vgf staining 
is localized to cortical tubules (one positive tubule highlighted with asterisks) and no staining was observed 
in the glomerulus (marked with #).  Blood urea nitrogen and serum creatinine analysis showed that tubular 
epithelial-specific Vgf deficiency results in aggravated renal impairment in the IRI (D-E), Cisplatin (F-G), 
and rhabdomyolysis (H-I) associated mouse models of AKI. In all the bar graphs (n=4-11 biologically 
independent samples), experimental values are presented as mean ± s.d. The height of error bar = 1 s.d. and 
p < 0.05 was indicated as statistically significant. One-way ANOVA followed by Tukey’s multiple-
comparison test (A-I) was carried out, and statistical significance is indicated by *p < 0.05, **p < 0.01, 
***p < 0.001. Scale bar (C): 100 µm.  
Figure 5: Renal protective effects of Vgf-derived peptide TLQP-21. (A) Kidney cortical tissue lysates from 
mock treated mice (0 hours) or mice undergoing AKI (IRI, Cisplatin, and Rhabdomyolysis- 24 hours) were 
used for measurement of TLQP-21 levels using an ELISA based assay. More than 2 fold increase in TLQP-
21 levels was observed in the control mice undergoing AKI. * indicates statistical significance as compared 
to respective mock or vehicle treated (0 hours) group. (B) Primary murine renal tubular cells of indicated 
genotypes were treated with 50 µM cisplatin and levels of TLQP-21 secreted in the media was assessed by 
an ELISA-based method. Cisplatin treatment resulted in TLQP-21 release into the media 12 hours post 
cisplatin treatment in the Wild type RTECs. (C) Littermate control and VgfPT−/- mice were treated with 
cisplatin (30 mg/kg) on Day 0, followed by intraperitoneal injection of either a scrambled peptide or TLQP-
21 (5 mg/kg in normal saline) on day 1 and 2. Renal damage was then examined at day 3. Blood urea 
nitrogen (D), serum creatinine (E), and histological analysis (F) showed that the TLQP-21 administration 
can partly reverse the aggravated cisplatin nephrotoxicity seen in the VgfPT−/- mice. In all the bar graphs 
(n = 8-9 biologically independent samples), experimental values are presented as mean ± s.d. The height of 
error bar = 1 s.d. and p < 0.05 was indicated as statistically significant. One-way ANOVA followed by 
Dunnett’s was carried out, and statistical significance is indicated by *p < 0.05, **p < 0.01, ***p < 0.001. 
 












Figure 6: Vgf is a Sox9 target gene. (A) Schematic representation of murine Vgf promoter, highlighting 
the putative Sox9 binding site. (B-C) HEK293 cells were stably transfected with empty plasmid or Sox9 
construct. The mock transfected cells (-) and Sox9 expressing cells (+) were then used for luciferase based 
reporter assays. The Vgf promoter sequences (-2000bp from TSS) was cloned in a luciferase reporter 
construct. Mock (-) and Sox9 (+) expressing cells were transiently co-transfected with reporter renila 
luciferase constructs (empty, Vgf or Vgfmut) and reference cypridina luciferase (normalizing control), 
followed by measurement of luciferase activity at 24 hours. The normalized luciferase activity of mock (-) 
group was then compared with the Sox9 (+) group. The results show that the Sox9 can activate transcription 
from the Vgf promoter. In the Vgfmut construct, the Sox9 binding site was mutated from ATTGTT to 
AACAAT. (D) Sox9 Chromatin immunoprecipitations (ChIP) were carried out from the renal tissues of 
control and Sox9PT-/- mice undergoing Ischemia, cisplatin nephrotoxicity, and rhabdomyolysis associated 
AKI. Subsequent qPCR analysis using primers specific for the murine Vgf promoter region showed that 
Sox9 can bind to Vgf promoter in vivo. (E-G) q-PCR based gene expression analysis was carried out in the 
renal tissues from littermate control and Sox9PT-/- mice under at indicated time-points after induction of 
kidney injury. The injury induced Vgf mRNA upregulation was suppressed in the Sox9PT-/- mice. (H) 
Immunoblot analysis of renal cortical tissues showed that AKI-induced Vgf protein induction is suppressed 
in the Sox9PT-/- mice. Blots are representative of three independent experiments. In all the bar graphs (n = 8-
9 biologically independent samples), experimental values are presented as mean ± s.d. The height of error 
bar = 1 s.d. and p < 0.05 was indicated as statistically significant. One-way ANOVA followed Tukey’s (C) 
or Dunnett’s (D-G) multiple-comparison test was carried out, and statistical significance is indicated by 
*p < 0.05, **p < 0.01, ***p < 0.001. 
Figure 7: Stress-induced Sox9-Vgf axis in human RTECs. HK-2 (human kidney 2), a renal tubular 
epithelial cell line derived from normal human kidney was used to examine the Sox9-Vgf axis. (A) HK-2 
cells were transiently transfected with control or two distinct Vgf targeting siRNA constructs, followed by 
cisplatin treatment. Immunoblot analysis showed that cisplatin treatment results in Vgf protein induction, 
which was significantly blocked by both the Vgf-targeting siRNAs. Measurement of cellular viability by 
(B) trypan blue staining, (C) MTT assay and (D) caspase activity showed that Vgf knockdown sensitizes 
HK-2 cells to cisplatin-associated cell death. (E) To examine the role of Sox9 in cisplatin-associated Vgf 
gene induction, we used RNAi-based knockdown of Sox9 in HK-2 cells. HK-2 cells were transiently 
transfected with control or two distinct Sox9 targeting siRNA constructs, followed by cisplatin treatment. 
Immunoblot analysis showed that Sox9-targeting siRNAs successfully knocked down Sox9 protein levels. 
Measurement of cellular viability by   Schematic representation of murine Vgf promoter, highlighting the 
putative Sox9 binding site. Importantly Sox9 knockdown suppressed Vgf protein upregulation. (F) q-PCR 
based gene expression analysis showed that RNAi-mediated Sox9 knock down suppressed cisplatin-
mediated Vgf mRNA upregulation. (G) Schematic representation of human Vgf promoter, highlighting the 
putative Sox9 binding site. (H) HEK293 cells were stably transfected with empty plasmid or Sox9 construct. 
The mock transfected cells (-) and Sox9 expressing cells (+) were then used for luciferase based reporter 
assays. The Vgf promoter sequences (-2000bp from TSS) was cloned in a luciferase reporter construct. 
Mock (-) and Sox9 (+) expressing cells were transiently co-transfected with reporter renila luciferase 
constructs (empty, Vgf or Vgfmut) and reference cypridina luciferase (normalizing control), followed by 
measurement of luciferase activity at 24 hours. The results show that the Sox9 can activate transcription 
from the Vgf promoter. In the Vgfmut construct, the Sox9 binding site was mutated from ATTGTT to 
AACAAT. In all the bar graphs (n=6-10 biologically independent samples), experimental values are 
presented as mean ± s.d. The height of error bar = 1 s.d. and p < 0.05 was indicated as statistically significant. 
One-way ANOVA followed Tukey’s multiple-comparison test was carried out, and statistical significance 
is indicated by *p < 0.05, **p < 0.01, ***p < 0.001. 










Figure 1: Mouse models of acute kidney injury. Ischemic, nephrotoxic, and rhabdomyolysis-associated acute kidney injury
was induced in 8-12 weeks old male C57BL/6J mice. Bilateral renal ischemia (30 minutes) was induced for 30 min followed
by reperfusion for 24 hours. Blood urea nitrogen (A), serum creatinine (B), and histological analysis (C) were performed to
examine renal function and damage. Rhabdomyolysis was induced in male mice by glycerol injection (7.5 ml/kg 50%
glycerol) in the hind-leg muscles followed by measurement of renal function (D-E) and histological analysis (F) of renal
damage. Nephrotoxicity was induced in mice by a single intraperitoneal injection of cisplatin (30 mg/kg), followed by BUN
(G), serum creatinine (H), and histological analysis (I) at the indicated time-points. (J) Representative H&E staining
depicting renal tubular damage (indicated by an asterisk) linked with ischemia, cisplatin-nephrotoxicity, and rhabdomyolysis
associated AKI. In all the bar graphs (n=8 biologically independent samples), experimental values are presented as
mean ± s.d. The height of error bar = 1 s.d. and p < 0.05 was indicated as statistically significant. Student’s t-test (A-I) was
carried out and statistical significance is indicated by *p < 0.05, **p < 0.01, ***p < 0.001. Scale bar (J): 100 µm.
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Figure 2: Transcriptome analysis of AKI-associated differentially expressed genes. Renal cortical tissues from control
(mock and vehicle treated) mice and mice undergoing AKI (IRI, cisplatin nephrotoxicity, and rhabdomyolysis) were
utilized for transcriptome analysis. (A) Principal component analysis (PCA) of bulk RNA-Seq data from control (n=8)
and AKI (n=4) groups showed that biological replicates clustered together across groups, signifying a high degree of
similarity. (B) Heatmap of differentially expressed genes during AKI. (D) Graphical depiction of top up-and down-
regulated genes in three distinct AKI models. (C) Venn diagram depicting common differentially expressed genes in the
AKI groups. In the three AKI groups, a common set of 1501 genes were found to differentially expressed as compared to
control group. (E-G) Gene expression analysis of Havcr1, Lcn2, and Vgf genes showed injury induced upregulation. In
all (E-G) the bar graphs (n=4 biologically independent samples), experimental values are presented as mean ± s.d. The
height of error bar = 1 s.d. and p < 0.05 was indicated as statistically significant. One-way ANOVA followed by
Dunnett’s (E-G) was carried out, and statistical significance is indicated by *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 3: Vgf is upregulated in the tubular epithelial cells during AKI. ROSAmT/mG were crossed with Ggt1-Cre mice to
generate transgenic mice that express membrane-localized EGFP in renal tubular epithelial cells, while the other cell types
express membrane localized tdTomato. (A) Representative image showing EGFP expressing renal tubules (arrows) and
tdTomato expression in the glomerulus (asterisks). (B-D) Renal Vgf expression was monitored at indicated time-points using
qPCR-based analysis. The results demonstrate Vgf gene induction during the early stages of AKI. (E) Human (HK-2) and
murine (BUMPT) tubular epithelial cell lines as well as murine primary tubular epithelial cells were treated with either vehicle
(PBS) or 50 µM cisplatin followed by gene expression analysis at 12 hours. Cisplatin treatment in vitro resulted in Vgf
mRNA induction in both the cell lines as well as primary tubular epithelial cells. In all the bar graphs (n=10-11 biologically
independent samples), experimental values are presented as mean ± s.d. The height of error bar = 1 s.d. and p < 0.05 was
indicated as statistically significant. One-way ANOVA followed by Dunnett’s (B-D) or Student’s t-test (E) was carried out,
and statistical significance is indicated by *p < 0.05, **p < 0.01, ***p < 0.001. Scale bar (A): 100 µm.
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Figure 4: RTEC-specific Vgf gene ablation aggravates AKI. RTEC-specific Vgf knockout mice were generated by
crossing Ggt1-Cre mice with Vgf-floxed mice. 8-12 weeks old littermate control and Vgf conditional knockout male mice
(indicated by VgfPT−/-) were then challenged with bilateral renal ischemia (30 minutes), cisplatin (30 mg/kg, single
intraperitoneal injection) treatment, or glycerol-induce rhabdomyolysis (7.5 ml/kg 50% glycerol in the hind-leg muscles)
followed by examination of renal structure and function. (A-B) Immunoblot analysis of Vgf protein levels was performed
using renal cortical tissues from the control and Vgf deficient mice followed by densitometric analysis (normalized to β-
actin levels) using ImageJ. The graph depicts relative Vgf protein levels and shows successful gene knockout in the renal
tissues. Blots are representative of three independent experiments. (C) Immunofluorescence analysis of renal cortical tissues
from control and VgfPT-/- mice challenged with IRI shows that Vgf staining is localized to cortical tubules (one positive
tubule highlighted with asterisks) and no staining was observed in the glomerulus (marked with #). Blood urea nitrogen and
serum creatinine analysis showed that tubular epithelial-specific Vgf deficiency results in aggravated renal impairment in
the IRI (D-E), Cisplatin (F-G), and rhabdomyolysis (H-I) associated mouse models of AKI. In all the bar graphs (n=4-11
biologically independent samples), experimental values are presented as mean ± s.d. The height of error bar = 1 s.d. and
p < 0.05 was indicated as statistically significant. One-way ANOVA followed by Tukey’s multiple-comparison test (A-I)
was carried out, and statistical significance is indicated by *p < 0.05, **p < 0.01, ***p < 0.001. Scale bar (C): 100 µm.
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Figure 5: Renal protective effects of Vgf-derived peptide TLQP-21. (A) Kidney cortical tissue lysates from mock treated
mice (0 hours) or mice undergoing AKI (IRI, Cisplatin, and Rhabdomyolysis- 24 hours) were used for measurement of
TLQP-21 levels using an ELISA based assay. More than 2 fold increase in TLQP-21 levels was observed in the control
mice undergoing AKI. * indicates statistical significance as compared to respective mock or vehicle treated (0 hours) group.
(B) Primary murine renal tubular cells of indicated genotypes were treated with 50 µM cisplatin and levels of TLQP-21
secreted in the media was assessed by an ELISA-based method. Cisplatin treatment resulted in TLQP-21 release into the
media 12 hours post cisplatin treatment in the Wild type RTECs. (C) Littermate control and VgfPT−/- mice were treated with
cisplatin (30 mg/kg) on Day 0, followed by intraperitoneal injection of either a scrambled peptide or TLQP-21 (5 mg/kg in
normal saline) on day 1 and 2. Renal damage was then examined at day 3. Blood urea nitrogen (D), serum creatinine (E),
and histological analysis (F) showed that the TLQP-21 administration can partly reverse the aggravated cisplatin
nephrotoxicity seen in the VgfPT−/- mice. In all the bar graphs (n = 8-9 biologically independent samples), experimental
values are presented as mean ± s.d. The height of error bar = 1 s.d. and p < 0.05 was indicated as statistically significant.
One-way ANOVA followed by Dunnett’s was carried out, and statistical significance is indicated by *p < 0.05, **p < 0.01,
***p < 0.001.
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Figure 6: Vgf is a Sox9 target gene. (A) Schematic representation of murine Vgf promoter, highlighting the putative Sox9
binding site. (B-C) HEK293 cells were stably transfected with empty plasmid or Sox9 construct. The mock transfected cells
(-) and Sox9 expressing cells (+) were then used for luciferase based reporter assays. The Vgf promoter sequences (-2000bp
from TSS) was cloned in a luciferase reporter construct. Mock (-) and Sox9 (+) expressing cells were transiently co-
transfected with reporter renila luciferase constructs (empty, Vgf or Vgfmut) and reference cypridina luciferase (normalizing
control), followed by measurement of luciferase activity at 24 hours. The normalized luciferase activity of mock (-) group
was then compared with the Sox9 (+) group. The results show that the Sox9 can activate transcription from the Vgf
promoter. In the Vgfmut construct, the Sox9 binding site was mutated from ATTGTT to AACAAT. (D) Sox9 Chromatin
immunoprecipitations (ChIP) were carried out from the renal tissues of control and Sox9PT-/- mice undergoing Ischemia,
cisplatin nephrotoxicity, and rhabdomyolysis associated AKI. Subsequent qPCR analysis using primers specific for the
murine Vgf promoter region showed that Sox9 can bind to Vgf promoter in vivo. (E-G) q-PCR based gene expression
analysis was carried out in the renal tissues from littermate control and Sox9PT-/- mice under at indicated time-points after
induction of kidney injury. The injury induced Vgf mRNA upregulation was suppressed in the Sox9PT-/- mice. (H)
Immunoblot analysis of renal cortical tissues showed that AKI-induced Vgf protein induction is suppressed in the Sox9PT-/-
mice. Blots are representative of three independent experiments. In all the bar graphs (n = 8-9 biologically independent
samples), experimental values are presented as mean ± s.d. The height of error bar = 1 s.d. and p < 0.05 was indicated as
statistically significant. One-way ANOVA followed Tukey’s (C) or Dunnett’s (D-G) multiple-comparison test was carried
out, and statistical significance is indicated by *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 7: Stress-induced Sox9-Vgf axis in human RTECs. HK-2 (human kidney 2), a renal tubular epithelial cell line
derived from normal human kidney was used to examine the Sox9-Vgf axis. (A) HK-2 cells were transiently
transfected with control or two distinct Vgf targeting siRNA constructs, followed by cisplatin treatment. Immunoblot
analysis showed that cisplatin treatment results in Vgf protein induction, which was significantly blocked by both the
Vgf-targeting siRNAs. Measurement of cellular viability by (B) trypan blue staining, (C) MTT assay and (D) caspase
activity showed that Vgf knockdown sensitizes HK-2 cells to cisplatin-associated cell death. (E) To examine the role of
Sox9 in cisplatin-associated Vgf gene induction, we used RNAi-based knockdown of Sox9 in HK-2 cells. HK-2 cells
were transiently transfected with control or two distinct Sox9 targeting siRNA constructs, followed by cisplatin
treatment. Immunoblot analysis showed that Sox9-targeting siRNAs successfully knocked down Sox9 protein levels.
Measurement of cellular viability by Schematic representation of murine Vgf promoter, highlighting the putative Sox9
binding site. Importantly Sox9 knockdown suppressed Vgf protein upregulation. (F) q-PCR based gene expression
analysis showed that RNAi-mediated Sox9 knock down suppressed cisplatin-mediated Vgf mRNA upregulation. (G)
Schematic representation of human Vgf promoter, highlighting the putative Sox9 binding site. (H) HEK293 cells were
stably transfected with empty plasmid or Sox9 construct. The mock transfected cells (-) and Sox9 expressing cells (+)
were then used for luciferase based reporter assays. The Vgf promoter sequences (-2000bp from TSS) was cloned in a
luciferase reporter construct. Mock (-) and Sox9 (+) expressing cells were transiently co-transfected with reporter renila
luciferase constructs (empty, Vgf or Vgfmut) and reference cypridina luciferase (normalizing control), followed by
measurement of luciferase activity at 24 hours. The results show that the Sox9 can activate transcription from the Vgf
promoter. In the Vgfmut construct, the Sox9 binding site was mutated from ATTGTT to AACAAT. In all the bar graphs
(n=6-10 biologically independent samples), experimental values are presented as mean ± s.d. The height of error
bar = 1 s.d. and p < 0.05 was indicated as statistically significant. One-way ANOVA followed Tukey’s multiple-
comparison test was carried out, and statistical significance is indicated by *p < 0.05, **p < 0.01, ***p < 0.001.
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